Resources Repository
-
ReviewPublication 2017Quality of Life as an Outcome of Opioid Use Disorder Treatment
The recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there …
The recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there is little evidence regarding health-related quality-of-life (HRQoL) outcomes in treatment programs. Measuring HRQoL represents an opportunity to consider outcomes of opioid use disorder treatment that are more patient-centered and more relevant to overall health than abstinence alone. This systematic literature review explores the extent to which the collection of HRQoL by opioid treatment programs is documented in the treatment program literature.…
Evidence Synthesis | Preferences/Values | Chronic Disease/Risk | Mental Health | Health Outcomes | Social Determinants | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2022Comparing Health Gains, Costs & Cost-Effectiveness of Interventions in Australia & New Zealand
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New …
This paper synthesizes the health gains, costs, and cost-effectiveness of health interventions in Australia and New Zealand (NZ) from studies conducted with comparable methods, and reports results in the form of an online interactive league table. Studies from the Australia Cost-Effectiveness research and NZ Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programmes and studies were included which reported health-adjusted life years (HALYs) and net health system costs and/or incremental cost-effectiveness ratios, used a time horizon of…
Priority Setting/Ethics | Chronic Disease/Risk | Mental Health | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Asia & Pacific | Oceania -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Evidence Synthesis | Priority Setting/Ethics | Chronic Disease/Risk | Cost-Effectiveness Analysis | Health/Medicine | Global -
ArticlePublication 2017Benefit and Harm of Intensive Blood Pressure Treatment: Derivation and Validation of Risk Models Using Data from the Sprint and Accord Trials
Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some …
Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. The authors sought to create risk calculators to estimate individual patients’ chances of benefit and harm from intensive treatment. They developed statistical models of cardiovascular events and serious adverse events from individual participant data from the Systolic Blood Pressure Intervention Trial (SPRINT) of intensive blood pressure treatment (N = 9,069 with complete covariate data) and validated them…
Evidence Synthesis | Probability/Bayes | Chronic Disease/Risk | Health Outcomes -
ReviewPublication 2016Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases …
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and…
Priority Setting/Ethics | Chronic Disease/Risk | Mental Health | Costing Methods | Cost-Effectiveness Analysis | Technology Assessment | Child/Nutrition | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Food/Agriculture | Health/Medicine | Latin America & Caribbean -
ArticlePublication 2016Estimating Benefits of Regulations Affecting Addictive Goods
The question of how to evaluate lost consumer surplus in benefit−cost analyses is controversial. There …
The question of how to evaluate lost consumer surplus in benefit−cost analyses is controversial. There are clear health benefits of regulations that curb consumption of goods with health risks, such as tobacco products and foods high in fats, calories, sugar, and sodium. Yet, if regulations cause consumers to give up goods they like, the health benefits they experience may be offset by some utility loss, which benefit−cost analyses of regulations need to take into account.…
Preferences/Values | Decision Theory | Mental Health | Benefit-Cost Analysis | Health/Medicine -
ArticlePublication 2016Measuring Benefits of Opioid Misuse Treatment: HRQOL of Opioid-Dependent Individuals and Spouses
This study sought to understand how the general public views the quality of life effects …
This study sought to understand how the general public views the quality of life effects of opioid misuse and opioid use disorder on an individual and his/her spouse, measured in terms used in economic evaluations. The study design was a cross-sectional internet survey of a US population-representative respondent panel conducted December 2013-January 2014, with a total of 2054 randomly selected adults, of whom 51.1% were male. The mean individual utility ranged from 0.574 for active injection…
Preferences/Values | Chronic Disease/Risk | Mental Health | Health Outcomes | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Priority Setting/Ethics | Chronic Disease/Risk | Mental Health | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2015A Conceptual Model for Breast, Cervical, and Colorectal Cancer Screening
General frameworks of the cancer screening process are available, but none directly compare the process …
General frameworks of the cancer screening process are available, but none directly compare the process in detail across different organ sites. This limits the ability of medical and public health professionals to develop and evaluate coordinated screening programs that apply resources and population management strategies available for one cancer site to other sites. This paper presents a conceptual model that incorporates a single screening episode for breast, cervical, and colorectal cancers into a unified framework based…
Evidence Synthesis | Preferences/Values | Chronic Disease/Risk | Health Outcomes | Test Performance | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Clinical Care | Health/Medicine | Science/Technology | North America